{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-027199","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.336118+00:00","generated_at":"2026-06-04T06:16:09.483831+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TFF Pharmaceuticals FY2023 net loss $21.2M, cash $5.5M; TFF TAC positive data","bullets":["Cash $5.5M at Dec 31, 2023; raised $1.2M gross in March 2024 offering plus warrants at $8.00.","FY2023 net loss $21.2M (down from $31.8M in 2022); R&D $12.1M (-35%), G&A $10.6M (-23%).","Phase 2 TFF TAC: 8/8 patients transitioned from oral Tacrolimus, no acute rejection, 4/4 continued to long-term extension.","TFF VORI: 5/6 completed patients achieved clinical and mycologic response; no IPA-related mortality.","Company prioritizing TFF TAC, exploring strategic alternatives for TFF VORI; new board members appointed in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-027199","json":"https://secwatch.observer/filing/0001213900-24-027199.json","markdown":"https://secwatch.observer/filing/0001213900-24-027199.md","text":"https://secwatch.observer/filing/0001213900-24-027199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/0001213900-24-027199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/ea0202827-8k_tff.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:16:09.483831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5df6d3980acf1ba5affbd93ba63dbd4edba5dbcd","claim":"TFF Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $21.2 million.","evidence_excerpt":"Net loss was $21.2 million for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/0001213900-24-027199-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $21.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}